Table 2 Neutralizing monoclonal antibodies under investigation in clinical trials against COVID-19
From: Potential therapeutic options for COVID-19: an update on current evidence
Target | Name | Related disease | Trial ID |
|---|---|---|---|
IL-6 receptor | Tocilizumab | Rheumatoid arthritis | NCT04730323 |
Sarilumab | Rheumatoid arthritis | NCT04315298 | |
Levilimab | Rheumatoid arthritis | NCT04397562 | |
IL-6 | Siltuximab | Rheumatoid arthritis | NCT04329650 |
Clazakizumab | Rheumatoid arthritis | NCT04494724 | |
Sirukumab | Rheumatoid arthritis | NCT04380961 | |
Olokizumab | Rheumatoid arthritis | NCT04380519 | |
IL-1 receptor | Anakinra | Rheumatoid arthritis | NCT04366232 |
IL1 β | Canakinumab | systemic juvenile idiopathic arthritis and active Still's disease | NCT04362813 |
GM-CSF receptor | Mavrilimumab | Rheumatoid arthritis | NCT04447469 |
GM-CSF | Lenzilumab | Chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia | NCT04583969 |
Gimsilumab | Rheumatoid arthritis, multiple sclerosis, asthma, cancer | NCT04351243 | |
Otilimab | Rheumatoid arthritis | NCT04376684 | |
TJ003234 | Rheumatoid arthritis, cytokine release syndrome, osteoarthritis | NCT04341116 | |
IFN-γ | Emapalumab | Hemophagocytic lymphohistiocytosis | NCT04324021 |
TNF-α | Adalimumab | Rheumatoid arthritis | NCT04705844 |
Infliximab | Autoimmune diseases | NCT04425538 | |
IL-17 | Secukinumab | Psoriasis, ankylosing spondylitis, psoriatic arthritis | NCT04403243 |
Ixekizumab | Autoimmune diseases | NCT04724629 | |
IL-12/IL-23 | Risankizumab | Moderate to severe plaque psoriasis | NCT04583956 |